WO2006029740A2 - Transdermales therapeutisches system mit einer haftschicht, verfahren zum silikonisieren einer rückschicht des systems und verwendung der rückschicht - Google Patents

Transdermales therapeutisches system mit einer haftschicht, verfahren zum silikonisieren einer rückschicht des systems und verwendung der rückschicht Download PDF

Info

Publication number
WO2006029740A2
WO2006029740A2 PCT/EP2005/009547 EP2005009547W WO2006029740A2 WO 2006029740 A2 WO2006029740 A2 WO 2006029740A2 EP 2005009547 W EP2005009547 W EP 2005009547W WO 2006029740 A2 WO2006029740 A2 WO 2006029740A2
Authority
WO
WIPO (PCT)
Prior art keywords
layer
backing layer
transdermal therapeutic
therapeutic system
adhesive
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2005/009547
Other languages
German (de)
English (en)
French (fr)
Other versions
WO2006029740A3 (de
Inventor
Walter Müller
Johannes Leonhard
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LTS Lohmann Therapie Systeme AG
Original Assignee
LTS Lohmann Therapie Systeme AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to AU2005284436A priority Critical patent/AU2005284436B2/en
Priority to PH1/2012/501165A priority patent/PH12012501165A1/en
Priority to CA2578534A priority patent/CA2578534C/en
Priority to JP2007530634A priority patent/JP4921371B2/ja
Priority to DK05777179.2T priority patent/DK1791533T3/da
Priority to EP05777179A priority patent/EP1791533B1/de
Priority to NZ553485A priority patent/NZ553485A/en
Priority to PL05777179T priority patent/PL1791533T3/pl
Priority to SI200531700T priority patent/SI1791533T1/sl
Priority to US11/661,530 priority patent/US9226903B2/en
Priority to KR1020077005735A priority patent/KR101297903B1/ko
Priority to MX2007002966A priority patent/MX2007002966A/es
Application filed by LTS Lohmann Therapie Systeme AG filed Critical LTS Lohmann Therapie Systeme AG
Priority to BRPI0515270A priority patent/BRPI0515270B8/pt
Priority to ES05777179T priority patent/ES2406958T3/es
Publication of WO2006029740A2 publication Critical patent/WO2006029740A2/de
Publication of WO2006029740A3 publication Critical patent/WO2006029740A3/de
Priority to IL181337A priority patent/IL181337A/en
Anticipated expiration legal-status Critical
Priority to US14/953,789 priority patent/US10034841B2/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7069—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. polysiloxane, polyesters, polyurethane, polyethylene oxide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00—Bandages or dressings; Absorbent pads
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00—Bandages or dressings; Absorbent pads
    • A61F13/02—Adhesive bandages or dressings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00—Bandages or dressings; Absorbent pads
    • A61F13/02—Adhesive bandages or dressings
    • A61F13/023—Adhesive bandages or dressings wound covering film layers without a fluid retention layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00—Bandages or dressings; Absorbent pads
    • A61F13/02—Adhesive bandages or dressings
    • A61F13/0246—Adhesive bandages or dressings characterised by the skin-adhering layer
    • A61F13/0253—Adhesive bandages or dressings characterised by the skin-adhering layer characterized by the adhesive material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08K—Use of inorganic or non-macromolecular organic substances as compounding ingredients
    • C08K3/00—Use of inorganic substances as compounding ingredients
    • C08K3/34—Silicon-containing compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00—Bandages or dressings; Absorbent pads
    • A61F13/02—Adhesive bandages or dressings
    • A61F13/0246—Adhesive bandages or dressings characterised by the skin-adhering layer

Definitions

  • Transdermal therapeutic system with an adhesive layer method for siliconizing a backing layer of the system and use of the backing layer
  • the invention relates to a transdermal therapeutic system comprising a backing layer, a polymer layer in contact with the backing layer comprising silicone adhesives and a releasable protective layer in contact with the polymer layer, a process for producing a siliconized backing layer of the system, and the use of the backs - layer.
  • TTS Transdermal therapeutic systems
  • medicated patches have become an established drug form. Nevertheless, some problems associated with this dosage form have not been satisfactorily resolved to date.
  • matrix systems or systems which have a structure related to the matrix systems.
  • TTS consists of a backing layer, a preferably self-adhesive matrix layer containing active ingredient and a protective layer to be removed before use.
  • a matrix system or matrix TTS consists of a backing layer, a preferably self-adhesive matrix layer containing active ingredient and a protective layer to be removed before use.
  • the formation of a more or less weak dark margin around the patch on the skin is observed or remain on removal of the TTS adhesive residue on the skin. This phenomenon is particularly noticeable in TTS suitable for use over several days.
  • the cause of both phenomena is insufficient adhesion of the plaster matrix to the back layer of the system.
  • This inadequate adhesion and body movement at the point of application causes leakage of the adhesive at the edges of the system and the leaked adhesive may come into contact with the clothing. Due to the contact with the clothing, fabric fibers hang on the leaked adhesive and usually give it a dark appearance. After removal of the TTS, the leaked adhesive remains in the form of dark marks on the skin. If the adhesion to the backing layer is particularly poor, the matrix can also detach from the backing layer in a planar manner and remain on the skin. Particularly susceptible to such phenomena are adhesives based on silicones.
  • silicone adhesives are very non-polar and therefore adhere relatively poorly to the more or less polar surfaces of the backing layer, which is usually made of polyethylene terephthalate (PET).
  • PET polyethylene terephthalate
  • silicone adhesives have only a low degree of cohesion and therefore have a particularly pronounced tendency to have kicked out of the system. Silicone adhesives therefore behave like a viscous liquid and spreading on a larger surface is therefore also referred to as "cold flow”.
  • the object of the present invention is therefore to improve the adhesion of the backing layer in a trans dermal therapeutic system with the active ingredient-containing polymer layer containing at least one silicone adhesive, and to prevent leakage of silicone adhesive from the system largely.
  • transdermal therapeutic system described above in such a way that the contact side of the backing layer is equipped with an adhesive layer obtained by siliconization.
  • the adhesive layer is an organopolysiloxane layer.
  • the adhesive layer contains organopolysiloxanes with vinyl groups and organopolysiloxanes with Si-H groups.
  • the backing layer is preferably a plastic film selected from the group consisting of polyester, in particular polyethylene terephthalate, polypropylene, polyethylene, polyurethane, EVA layers in combination with polyester, polyvinylidene chloride, polyaramid ethylene (meth) acrylate copolymers.
  • the process according to the invention for producing a backing layer which is used in a transdermal therapeutic system is characterized in that the surface of the backing layer to be brought into contact with a polymer layer which is equipped with microreservoirs is siliconized. This is preferably done in such a way that organopolysiloxanes are mixed with vinyl groups and organopolysiloxanes having functional Si-H groups and the surface of the backing layer is coated with the mixture in the presence of a catalyst. Thereafter, the coated surface of the backing layer is heat treated until formation of an organopolysiloxane layer firmly anchored on the backing layer.
  • Catalyst for example, a platinum catalyst is used. The heat treatment takes place in a heating furnace or in a heat transfer tunnel. The temperature is about 80 to 100 ° C, but may also be below 80 ° C.
  • any self-adhesive system must be protected by a removable protective layer before use.
  • the protective layer may be made of various materials such as e.g. PET, polyethylene or polypropylene are made and specially treated on the side in contact with the adhesive in order to make it as easy as possible to detach it from the adhesive layer.
  • this surface treatment usually consists of a so-called siliconization. In this siliconization, in a coating process, e.g.
  • Organopolysiloxanes are coated with vinyl groups and organopolysiloxanes having SiH-functional groups in a mixture in the presence of a platinum catalyst on the film to be treated, wherein a heat-treatment forms an organopolysiloxane layer firmly adhering to the substrate.
  • non-silicone based adhesives such as polyacrylate adhesive
  • silicone adhesives adhere extremely well to such surfaces.
  • drug-free patches based on silicone adhesives and a backing layer treated in this way leave behind considerably less residual liming after removal on the skin and that the tendency to form "black" edges around the plaster is considerably reduced.
  • silicone adhesive-based TTS the permeation rate of the drug through the skin is increased by the external application of heat to the applied TTS.
  • Such systems are described in detail, for example, in US Pat. No. 6,488,959 A1 and US Pat. No. 6,261,595 A1. Due to the temperature, which may well rise up to about 45 ° C, the tendency of the silicone adhesive for spreading by cold flow is massively increased under such conditions is increased with the formation of dark edges around the plaster and the retention of adhesive residues on the Skin after removal of the plaster. In such systems, a siliconization of the backing layer is of great advantage because, despite the application of heat spreading of the adhesive is largely avoided.
  • microreservoir systems based on silicone adhesives and ambiphilic solvents for the active ingredient.
  • microreservoir systems are described in detail in EP 1 191 927 Bl.
  • the active ingredient is dissolved in an ambiphilic solvent such as dipropylene glycol or 1,3-butanediol and the solution is dispersed in the solution of the adhesive.
  • the dispersion is coated on the protective layer of the later TTS, the solvent of the adhesive is removed and the dried film is laminated with the backing layer. It has now been found that an unsiliconized backing layer does not adhere to such a film practically.
  • the cause is the formation of a very thin film of the ambiphilic solvent on the surface of the dried active substance-containing film.
  • a change in the manufacturing process for example a coating directly on the backing layer, does not improve the adhesion of the dried film.
  • a siliconized backing layer regardless of the chemical nature of the film itself, gives very good adhesion immediately after contact with a microreservoir-containing layer.
  • improved adhesion can also be achieved by the use of less inert materials, such as copolymers of ethylene and vinyl acetate, for the backsheet of such systems, such materials have the disadvantage that they also take active ingredient in addition to the solvent.
  • Microreservoir systems as described above are therefore best practiced using siliconized backing layers of polyester or similar inert materials.
  • the sole figure shows a transdermal therapeutic system 5 comprising a backing layer 1, an adhesive layer 4 anchored on the backing layer, a polymer layer 2 and a peelable protective layer 3.
  • the adhesive layer 4 is an organopolysiloxane layer containing organopolysiloxanes having vinyl groups and organopolysiloxanes having Si-H functional groups.
  • the backing layer 1 consists of a plastic film. Suitable plastics are polyesters, in particular polyethylene terephthalate, polypropylene, polyethylene, polyurethane, EVA layers in combination with polyester, PVDC, polyaramides, ethylene (meth) acrylate copolymers.
  • the silicone adhesives in the polymer layer 2 are selected, for example, from the group of polysiloxanes and mixtures of polysiloxanes.
  • microreservoires which contain at least one active ingredient dissolved in an ambiphilic solvent.
  • Suitable ambiphilic solvents are 1,3-butanediol, diethylene glycol monomethyl ether, diethylene glycol dimethyl ether, dipropylene glycol, propylene glycol, tetrahydrofurfuryl alcohol, diethylene glycol monobutyl ether, carboxylic esters of tri- and diethylene glycol, polyoxyethylated fatty alcohols of 6 to 18 carbon atoms.
  • the protective layer 3 protrudes on both sides of the polymer layer 2, so that it is easily graspable and removable.

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Polymers & Plastics (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)
PCT/EP2005/009547 2004-09-13 2005-09-06 Transdermales therapeutisches system mit einer haftschicht, verfahren zum silikonisieren einer rückschicht des systems und verwendung der rückschicht Ceased WO2006029740A2 (de)

Priority Applications (16)

Application Number Priority Date Filing Date Title
KR1020077005735A KR101297903B1 (ko) 2004-09-13 2005-09-06 접착제 층을 포함하는 경피 치료 시스템, 상기 시스템의 배면 층을 실리콘화시키는 방법 및 상기 배면 층의 용도
CA2578534A CA2578534C (en) 2004-09-13 2005-09-06 Transdermal therapeutic system comprising an adhesive layer, method of siliconizing the back layer of the system and use of said back layer
JP2007530634A JP4921371B2 (ja) 2004-09-13 2005-09-06 接着剤層を含む経皮治療システム、このシステムの支持層をシリコン処理する方法およびこの支持層の使用
DK05777179.2T DK1791533T3 (da) 2004-09-13 2005-09-06 Transdermalt terapeutisk system med et klæbelag, fremgangsmåde til silikonebehandling af et bagsidelag i systemet samt anvendelse af bagsidelaget
EP05777179A EP1791533B1 (de) 2004-09-13 2005-09-06 Transdermales therapeutisches system mit einer haftschicht, verfahren zum silikonisieren einer rückschicht des systems und verwendung der rückschicht
NZ553485A NZ553485A (en) 2004-09-13 2005-09-06 Transdermal therapeutic system comprising an adhesive layer, method of siliconizing the back layer of the system and use of said back layer
PL05777179T PL1791533T3 (pl) 2004-09-13 2005-09-06 Transdermalny system terapeutyczny zawierający warstwę przyczepną, sposób silikonowania warstwy tylnej systemu i zastosowanie tej warstwy tylnej
SI200531700T SI1791533T1 (sl) 2004-09-13 2005-09-06 Transdermalni terapevtski sistem z adhezivno plastjo, postopek za silikoniziranje hrbtne plasti sistema in uporaba hrbtne plasti
US11/661,530 US9226903B2 (en) 2004-09-13 2005-09-06 Transdermal therapeutic system comprising an adhesive layer method for siliconizing the back layer or the system and use of said back layer
AU2005284436A AU2005284436B2 (en) 2004-09-13 2005-09-06 Transdermal therapeutic system comprising an adhesive layer method for siliconizing the back layer of the system and use of said back layer
PH1/2012/501165A PH12012501165A1 (en) 2004-09-13 2005-09-06 Transdermal therapeutic system comprising an adhesive layer method for siliconizing the back layer of the system and use of said back layer
MX2007002966A MX2007002966A (es) 2004-09-13 2005-09-06 Sistema terapeutico transdermal con una capa de respaldo y procedimiento para la fabricacion de la misma.
BRPI0515270A BRPI0515270B8 (pt) 2004-09-13 2005-09-06 sistema terapêutico transdérmico com uma camada adesiva, processo para siliconizar uma camada posterior do sistema e uso da camada posterior
ES05777179T ES2406958T3 (es) 2004-09-13 2005-09-06 Sistema terapéutico transdermal con una capa adhesiva, procedimiento para la siliconización de una capa de respaldo del sistema y utilización de la capa de respaldo
IL181337A IL181337A (en) 2004-09-13 2007-02-14 Transdermal therapeutic system comprising an adhesive layer, method for siliconizing the backing layer of the system and use of said backing layer
US14/953,789 US10034841B2 (en) 2004-09-13 2015-11-30 Transdermal therapeutic system comprising an adhesive layer method for siliconizing the back layer of the system and use of said back layer

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102004044578A DE102004044578A1 (de) 2004-09-13 2004-09-13 Transdermales therapeutisches System mit einer Haftschicht, Verfahren zum Silikonisieren einer Rückschicht des Systems und Verwendung der Rückschicht
DE102004044578.8 2004-09-13

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US11/661,530 A-371-Of-International US9226903B2 (en) 2004-09-13 2005-09-06 Transdermal therapeutic system comprising an adhesive layer method for siliconizing the back layer or the system and use of said back layer
US14/953,789 Continuation US10034841B2 (en) 2004-09-13 2015-11-30 Transdermal therapeutic system comprising an adhesive layer method for siliconizing the back layer of the system and use of said back layer

Publications (2)

Publication Number Publication Date
WO2006029740A2 true WO2006029740A2 (de) 2006-03-23
WO2006029740A3 WO2006029740A3 (de) 2006-06-22

Family

ID=35911201

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2005/009547 Ceased WO2006029740A2 (de) 2004-09-13 2005-09-06 Transdermales therapeutisches system mit einer haftschicht, verfahren zum silikonisieren einer rückschicht des systems und verwendung der rückschicht

Country Status (25)

Country Link
US (2) US9226903B2 (enExample)
EP (2) EP2529732B1 (enExample)
JP (1) JP4921371B2 (enExample)
KR (1) KR101297903B1 (enExample)
CN (2) CN102755305A (enExample)
AR (1) AR050621A1 (enExample)
AU (1) AU2005284436B2 (enExample)
BR (1) BRPI0515270B8 (enExample)
CA (1) CA2578534C (enExample)
CY (2) CY1113997T1 (enExample)
DE (1) DE102004044578A1 (enExample)
DK (2) DK1791533T3 (enExample)
ES (2) ES2406958T3 (enExample)
IL (1) IL181337A (enExample)
LT (1) LT2529732T (enExample)
MX (1) MX2007002966A (enExample)
NZ (1) NZ553485A (enExample)
PH (1) PH12012501165A1 (enExample)
PL (2) PL1791533T3 (enExample)
PT (2) PT2529732T (enExample)
RU (1) RU2398567C2 (enExample)
SI (2) SI1791533T1 (enExample)
TW (1) TWI383811B (enExample)
WO (1) WO2006029740A2 (enExample)
ZA (1) ZA200701138B (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8252321B2 (en) 2004-09-13 2012-08-28 Chrono Therapeutics, Inc. Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like
CA2580329C (en) 2004-09-13 2015-01-06 Chrono Therapeutics Inc. Biosynchronous transdermal drug delivery
US8518926B2 (en) * 2006-04-10 2013-08-27 Knopp Neurosciences, Inc. Compositions and methods of using (R)-pramipexole
US20070259930A1 (en) * 2006-04-10 2007-11-08 Knopp Neurosciences, Inc. Compositions and methods of using r(+) pramipexole
ES2379117T3 (es) * 2006-05-16 2012-04-20 Knopp Neurosciences, Inc. Composiciones de R(+) y S(-) pramipexol y métodos de utilización de las mismas
US8524695B2 (en) * 2006-12-14 2013-09-03 Knopp Neurosciences, Inc. Modified release formulations of (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine and methods of using the same
WO2008113056A2 (en) 2007-03-14 2008-09-18 Knopp Neurosciences, Inc. Synthesis of chirally purified substituted benzothiazole diamines
CN102186350A (zh) * 2008-08-19 2011-09-14 诺普神经科学股份有限公司 使用(r)-普拉克索的组合物与方法
US20110009460A1 (en) * 2009-06-19 2011-01-13 Valentin Gribkoff Compositions and methods for treating amyotrophic lateral sclerosis
US20130017259A1 (en) 2011-07-06 2013-01-17 The Parkinson's Institute Compositions and Methods for Treatment of Symptoms in Parkinson's Disease Patients
WO2013096816A1 (en) 2011-12-22 2013-06-27 Biogen Idec Ma Inc. Improved synthesis of amine substituted 4,5,6,7-tetrahydrobenzothiazole compounds
KR101850161B1 (ko) 2012-05-17 2018-04-19 도레이첨단소재 주식회사 경피흡수제에 적합하게 사용될 수 있는 릴리즈 라이너 및 그 제조방법
US9662313B2 (en) 2013-02-28 2017-05-30 Knopp Biosciences Llc Compositions and methods for treating amyotrophic lateral sclerosis in responders
US9468630B2 (en) 2013-07-12 2016-10-18 Knopp Biosciences Llc Compositions and methods for treating conditions related to increased eosinophils
SMT202100119T1 (it) 2013-07-12 2021-05-07 Knopp Biosciences Llc Trattamento dei livelli elevati di eosinofili e/o basofili
AU2014306597B2 (en) 2013-08-13 2018-05-17 Knopp Biosciences Llc Compositions and methods for treating chronic urticaria
EP3038467B1 (en) 2013-08-13 2020-07-29 Knopp Biosciences LLC Compositions and methods for treating plasma cell disorders and b-cell prolymphocytic disorders
US9827206B2 (en) * 2013-09-24 2017-11-28 Zodiac Coating Method for producing an adhesive material for medical application
EP2921184A1 (de) * 2014-03-19 2015-09-23 LTS LOHMANN Therapie-Systeme AG Überpflaster mit verbesserter Verträglichkeit und einer langen Haftungsdauer und Verfahren zu seiner Herstellung
CA2974324A1 (en) 2015-01-28 2016-08-04 Zita S. Netzel Drug delivery methods and systems
WO2016145373A1 (en) 2015-03-12 2016-09-15 Chrono Therapeutics Inc. Craving input and support system
EP3565617A1 (en) 2017-01-06 2019-11-13 Chrono Therapeutics Inc. Transdermal drug delivery devices and methods
US11596779B2 (en) 2018-05-29 2023-03-07 Morningside Venture Investments Limited Drug delivery methods and systems
CA3119992A1 (en) 2018-11-16 2020-05-22 Morningside Venture Investments Limited Thermally regulated transdermal drug delivery system

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3131734A1 (de) * 1981-08-11 1983-02-24 Bayer Ag, 5090 Leverkusen Hitzehaertbare organopolysiloxan-mischungen
US4806341A (en) * 1985-02-25 1989-02-21 Rutgers, The State University Of New Jersey Transdermal absorption dosage unit for narcotic analgesics and antagonists and process for administration
FR2619388A1 (fr) * 1987-08-14 1989-02-17 Rhone Poulenc Chimie Article stratifie souple pour adhesif de transfert
DE19738643C2 (de) 1997-09-04 2001-10-04 Lohmann Therapie Syst Lts Transdermales therapeutisches System mit dem Wirkstoff Scopolaminbase und Verfahren zu seiner Herstellung
US6433054B1 (en) * 1997-09-16 2002-08-13 Teijin Limited Gel-form pressure-sensitive adhesive, and adhesive material and adhesive medicinal preparation both containing the same
PL197492B1 (pl) * 1999-07-02 2008-04-30 Lohmann Therapie Syst Lts Transdermalny system terapeutyczny zawierający warstwę polimerową z zawartymi w niej mikrozbiornikami i sposób wytwarzania błon
US6261595B1 (en) 2000-02-29 2001-07-17 Zars, Inc. Transdermal drug patch with attached pocket for controlled heating device
DE10015783C2 (de) * 2000-03-30 2003-12-04 Lohmann Therapie Syst Lts Transdermales therapeutisches System zur Abgabe von Lerisetron und seine Verwendung
US6488599B2 (en) 2000-06-06 2002-12-03 Lifetime Products, Inc. System and method for basketball goal height adjustment
GB0017468D0 (en) * 2000-07-18 2000-08-30 Dow Corning Silicone release coating compositions
DE10060550C1 (de) * 2000-12-06 2002-04-18 Lohmann Therapie Syst Lts Transdermales therapeutisches System mit dem Wirkstoff Oxybutynin und Verfahren zur Herstellung Oxybutynin enthaltender Wirkstoffschichten
US20030224090A1 (en) * 2002-02-11 2003-12-04 Edizone, Lc Snacks of orally soluble edible films
ITRM20020378A1 (it) 2002-07-15 2004-01-15 Euro 3 S R L Dispositivo iniettore ipodermico attivabile.
RU2348397C2 (ru) * 2003-02-07 2009-03-10 Лтс Ломанн Терапи-Системе Аг Трансдермальная терапевтическая система, пригодная для использования тепла с целью ускорения проникновения биологически активных веществ, и ее применение
RU2349315C9 (ru) * 2003-04-14 2010-02-27 Лтс Ломанн Терапи-Системе Аг Терапевтический пластырь с полисилоксановой матрицей, содержащей капсаицин
US7407709B2 (en) * 2003-12-22 2008-08-05 3M Innovative Properties Company Silicone pressure sensitive adhesive and articles
JP5525121B2 (ja) * 2003-12-23 2014-06-18 モーメンテイブ・パーフオーマンス・マテリアルズ・ゲゼルシヤフト・ミツト・ベシユレンクテル・ハフツング 表面の性質の改変された硬化型シロキサン組成物
US20050282977A1 (en) * 2004-06-17 2005-12-22 Emil Stempel Cross-linked gel and pressure sensitive adhesive blend, and skin-attachable products using the same

Also Published As

Publication number Publication date
DK2529732T3 (en) 2017-09-18
IL181337A (en) 2014-09-30
CN101018545A (zh) 2007-08-15
RU2398567C2 (ru) 2010-09-10
CY1113997T1 (el) 2016-07-27
BRPI0515270B8 (pt) 2021-07-27
ES2406958T3 (es) 2013-06-10
AU2005284436B2 (en) 2011-02-17
BRPI0515270A (pt) 2008-07-15
CA2578534A1 (en) 2006-03-23
US20080026043A1 (en) 2008-01-31
EP2529732B1 (de) 2017-06-21
EP2529732A1 (de) 2012-12-05
CY1120228T1 (el) 2018-12-12
US10034841B2 (en) 2018-07-31
TW200621319A (en) 2006-07-01
JP4921371B2 (ja) 2012-04-25
ZA200701138B (en) 2008-08-27
PT2529732T (pt) 2017-07-17
SI1791533T1 (sl) 2013-05-31
TWI383811B (zh) 2013-02-01
DE102004044578A1 (de) 2006-03-30
CN102755305A (zh) 2012-10-31
WO2006029740A3 (de) 2006-06-22
AU2005284436A1 (en) 2006-03-23
PL2529732T3 (pl) 2017-12-29
NZ553485A (en) 2010-06-25
IL181337A0 (en) 2007-07-04
JP2008512411A (ja) 2008-04-24
CA2578534C (en) 2013-03-19
US20160074336A1 (en) 2016-03-17
ES2634439T3 (es) 2017-09-27
EP1791533B1 (de) 2013-03-06
DK1791533T3 (da) 2013-06-10
PL1791533T3 (pl) 2013-08-30
LT2529732T (lt) 2017-09-11
PT1791533E (pt) 2013-05-07
BRPI0515270B1 (pt) 2018-11-06
EP1791533A2 (de) 2007-06-06
KR20070053244A (ko) 2007-05-23
PH12012501165A1 (en) 2013-09-02
RU2007113674A (ru) 2008-10-27
AR050621A1 (es) 2006-11-08
MX2007002966A (es) 2007-04-27
US9226903B2 (en) 2016-01-05
SI2529732T1 (sl) 2017-10-30
KR101297903B1 (ko) 2013-08-22

Similar Documents

Publication Publication Date Title
EP1791533B1 (de) Transdermales therapeutisches system mit einer haftschicht, verfahren zum silikonisieren einer rückschicht des systems und verwendung der rückschicht
EP1855660B2 (de) Faserfreies transdermales therapeutisches system und verfahren zu seiner herstellung
DE1569901C2 (de) Verfahren zum Herstellen von porösen selbstklebenden Bändern oder Blättern
EP3297691B1 (de) Silikongelbeschichtete adhäsive schichtstruktur
EP3119444B1 (de) Überpflaster mit verbesserter verträglichkeit und einer langen haftungsdauer und verfahren zu seiner herstellung
DE60200311T2 (de) Klebefolie und Klebstoffzubereitung und Verfahren zur Herstellung
DE3843237C2 (enExample)
EP2120896B1 (de) Medizinisch wirksames pflaster
DE202018006232U1 (de) Ölige Pflanzenextrakte enthaltende Elemente und Pflaster, die derartige wirkstoffhaltige Elemente enthalten
EP3886821A1 (de) Transdermales therapeutisches system mit diffusionsbarriere
DE102018216244A1 (de) Transdermales therapeutisches System mit Barriereschicht
DE102004016591A1 (de) Medizinische Pflaster mit verringertem Kleberrückstand
DE10348046A1 (de) Verfahren zur Herstellung von Matrizes für transdermale oder topicale Wirkstoffsysteme
HK1175110A (en) Transdermal therapeutic system comprising an adhesive layer method for siliconizing the back layer of the system and use of said back layer
HK1105360A (en) Transdermal therapeutic system comprising an adhesive layer method for siliconizing the back layer of the system and use of said back layer
DE20321153U1 (de) Pflaster, enthaltend Fentanylum

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 200701138

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 12007500376

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: 181337

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 11661530

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 553485

Country of ref document: NZ

Ref document number: 2578534

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2005777179

Country of ref document: EP

Ref document number: 2005284436

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: MX/a/2007/002966

Country of ref document: MX

Ref document number: 2007530634

Country of ref document: JP

Ref document number: 1020077005735

Country of ref document: KR

Ref document number: 200580030536.7

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 1057/CHENP/2007

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 2005284436

Country of ref document: AU

Date of ref document: 20050906

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2005284436

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2007113674

Country of ref document: RU

WWP Wipo information: published in national office

Ref document number: 2005777179

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 11661530

Country of ref document: US

ENP Entry into the national phase

Ref document number: PI0515270

Country of ref document: BR